AN2728: Preliminary Phase I data

Preliminary data from an open-label Phase I trial in 33 patients with extensive psoriasis (mean involvement of 38% of total body surface area) showed that twice-daily topical 2% AN2728 for 8 days was well tolerated with no serious adverse events reported. Additionally, Anacor said that application of AN2728 on larger body surface areas led to higher plasma exposure levels, but did not correlate with greater adverse events. ...